Effectiveness of the Bedaquiline, Pretomanid, and Linezolid Regimen, With or Without Moxifloxacin, for Drug-Resistant Tuberculosis in Ukraine Under Programmatic Conditions
Year: 2025
Type: article
Abstract: Bedaquiline, pretomanid, and linezolid, with or without moxifloxacin, have revolutionized treatment for drug-resistant tuberculosis. In Ukraine, we observed an 86% success rate (394 of 460) under programmatic conditions when drugs were accessible, exceeding prior estimates (58%) and aligning with trial findings (80%-90%). However, access and implementation remain a concern in conflict-affected settings.
Source: Clinical Infectious Diseases
DOI: 10.1093/cid/ciaf214
Authors: Victor Naestholt Dahl, Ole Skouvig Pedersen, Tetiana Butova, Mykhailo Kuzhko, Olena Raznatovska, Andrii Fedorec, Vitalii Vekshyn, Valentyna Hlynenko, Nataliia Yevsiukova, Leonid Hryshchuk, Svitlana Kornaha, Nataliia Chursina, Natalia Kondratyuk, Lyubov Markovtsiy, Vasyl Skryp, Artemii Bogomolov, Tetiana Klymenko, Daria Yankovska, Mykola Ostrovskyy, Iryna Makoida, Daria Levandovska, Yuulia Shpak, Vitalii Didyk, Olha Siomak, Dmytro Butov
Institutions: Aarhus University Hospital, National Academy of Medical Sciences of Ukraine, Zaporizhzhia State Medical and Pharmaceutical University, Kharkiv National Medical University, I.Horbachevsky Ternopil National Medical University, Lesya Ukrainka Volyn National University, National Pirogov Memorial Medical University, Vinnytsya, Ivano-Frankivsk National Medical University
Language: English
Subfield: Infectious Diseases
Field: Medicine
Domain: Health Sciences
Open Access status: green
Award: G3119256286
OpenAlex ID: W4409789350